Effectiveness and safety of kamikihito, a traditional Japanese medicine, in managing anxiety among female patients with intractable chronic constipation. (February 2022)

• Record Type: Journal Article
• Authors: Kobayashi, Akiko; Nagashima, Keiko; Hu, Ailing; Harada, Yoshinao; Kobayashi, Hiroyuki
• Is Part Of: Complementary therapies in clinical practice. Volume 46(2022)
• Publication Date: 2022-02
• Subjects: Anxiety -- Constipation -- Gastrointestinal tract -- Metabolite -- Kampo medicine; Integrative medicine -- Periodicals; Integrative medicine -- Research -- Periodicals; Alternative medicine -- Periodicals; 615.5
• DOI: 10.1016/j.ctcp.2021.101526
• Languages: English
• ISSNs: 1744-3881

Abstract

Abstract: Background and purpose: The prevalence of anxiety in patients with chronic constipation is particularly high and these individuals are not necessarily satisfied by normal treatments targeting the gastrointestinal tract. Kamikihito, a traditional Japanese Kampo medicine, has been widely used to date in treating anxiety and neurosis in Japan. We conducted a single-arm, open-label pilot study of female patients with intractable chronic constipation and anxiety who took kamikihito by mouth for 12 weeks. Materials and methods: Validated symptom questionnaires on anxiety and gastrointestinal symptoms [the Profile of Mood States, second edition (POMS2); the State–Trait Anxiety Inventory (STAI); and the Gastrointestinal Symptom Rating Scale (GSRS)] were completed at each study visit. Plasma, salivary, and stool samples were also assessed to evaluate levels of clinical bioactive substances linked to stress and inflammation, oxidative levels, the metabolome profile, and gut microbiota. Results: Twenty-four patients completed this study. Anxiety was significantly reduced at four and 12 weeks (Tension–Anxiety subscale of the POMS2, p = 0.006 and p = 0.039; Trait anxiety score of the STAI, p < 0.001 and p = 0.034), while the total GSRS score was improved at 12 weeks (p = 0.039). Targeted metabolomics in plasma showed significant alterations in some metabolites associated with psychological symptoms, such as O-phosphoethanolamine. No significant differences were found between pre- and posttreatment levels of clinical bioactive substances related to stress and inflammation, oxidative levels, and the gut microbiota in this cohort. No serious adverse events occurred. Conclusion: Kamikihito ameliorated psychological and gastrointestinal symptoms in patients with chronic constipation. In parallel with the onset of efficacy, kamikihito modulated some anxiety-related metabolites. Kamikihito was safe and well-tolerated. Highlights: Kamikihito alleviated anxiety in patients with chronic constipation. Kamikihito improved gastrointestinal symptoms in patients with chronic constipation. Kamikihito modulated some anxiety-related metabolites such as O-phosphoethanolamine. Kamikihito was safe and well-tolerated.